Lutiges 100 mg Vaginal tablets.
PDF Leaflet Revision Date: 29 June 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Luteal support in ART for infertile women.
Dosage (summary)
100 mg vaginally three times daily for 30 days post-oocyte retrieval.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during lactation; limited data on congenital anomalies in pregnancy.
Key Drug Interactions
- Inducers of CYP450-3A4 may decrease bioavailability
- Inhibitors of CYP450-3A4 may increase bioavailability
Contraindications
- Hypersensitivity
- Undiagnosed vaginal bleeding
- Missed abortion
- Severe hepatic dysfunction
- Breast or genital tract cancer
- Active thromboembolism
- Porphyria
Common side effects
- Headache
- Vulvovaginal disorders
- Uterine spasm
Counselling Points
- Use applicator for administration
- Report any severe headaches or vision changes
- Monitor for mood changes
Serious warnings
- Discontinue if myocardial infarction or thromboembolism suspected
- Caution in hepatic dysfunction
- Monitor diabetic patients
Important Disclaimer
The Lutiges 100 mg Vaginal tablets. professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
